ISPE
JULY 7, 2023
USP/BIOPHORUM Workshop on Continuous Manufacturing of Biologics Trudy Patterson Fri, 07/07/2023 - 08:45 Features July / August 2023 USP/BIOPHORUM Workshop on Continuous Manufacturing of Biologics John F. This article summarizes trends from the workshop and ponders next steps. Biotechnology and Bioengineering (2023): 1–6.
Pharma Marketing Network
JULY 27, 2023
Developing strong and meaningful relationships with Healthcare Professionals (HCPs) is vital for healthcare organizations, pharmaceutical companies, and medical device manufacturers alike. Consider organizing workshops, webinars, or conferences to share valuable medical insights, research, and developments.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
APRIL 13, 2023
Legislative hurdles aside, in the same way as any other pharmaceutical companies, psychedelics companies will need to obtain regulatory approvals in the countries where they will carry out clinical trials or market products. 8 Where does Europe stand globally in psychedelic medicines development?
pharmaphorum
OCTOBER 7, 2020
FDA regulator and founder of Barragan BioConsulting, where she offers Regulatory and Compliance consulting services to pharmaceutical companies globally. Interested in joining the conference and workshop you can register your place for only US$499 (conference) and US$299 (workshop) www.microbiologyeastcoast.com/PR9.
European Pharmaceutical Review
JULY 15, 2022
For many pharmaceutical companies, with complex, multinational operations, the challenge is devising a net-zero roadmap that is both effective and sustainable. Key stakeholders, including investors, want to see positive action on carbon emissions as part of a comprehensive environmental and social governance policy.
pharmaphorum
DECEMBER 7, 2021
Two-thirds of pharma companies feel well-resourced for digital HCP engagement, with all functions (digital, marketing, commercial and medical) having received increased budget and responsibility specifically for this purpose. It isn’t all doom and gloom, though. For more information visit www.epghealth.com.
pharmaphorum
SEPTEMBER 8, 2022
The open-access resources were developed over a period of 9 months, based on a mixed-methods study and comprehensive literature review, a series of workshops and focus groups with payers, as well as meeting with regulators. As yet, no new medical product has been approved on the basis of a digital endpoint.
Expert insights. Personalized for you.
52 
Let's personalize your content